LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Search

Charles River Laboratories International Inc

Geschlossen

BrancheGesundheitswesen

151.8 -2.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

151.57

Max

158.21

Schlüsselkennzahlen

By Trading Economics

Einkommen

-332M

-277M

Verkäufe

-11M

994M

EPS

2.43

Gewinnspanne

-27.816

Angestellte

18,300

EBITDA

730K

198M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+32.44% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

772M

8.7B

Vorheriger Eröffnungskurs

154.2

Vorheriger Schlusskurs

151.8

Nachrichtenstimmung

By Acuity

10%

90%

9 / 351 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Charles River Laboratories International Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. März 2026, 21:37 UTC

Akquisitionen, Fusionen, Übernahmen

Lensar and Alcon Agree to Terminate Merger

16. März 2026, 19:06 UTC

Wichtige Nachrichtenereignisse

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16. März 2026, 17:44 UTC

Akquisitionen, Fusionen, Übernahmen

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16. März 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. März 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Oil Prices Decline -- Market Talk

16. März 2026, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16. März 2026, 23:05 UTC

Market Talk

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16. März 2026, 21:56 UTC

Market Talk

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16. März 2026, 21:41 UTC

Market Talk
Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

16. März 2026, 21:41 UTC

Market Talk
Wichtige Nachrichtenereignisse

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16. März 2026, 20:59 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16. März 2026, 20:59 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16. März 2026, 20:59 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16. März 2026, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16. März 2026, 20:51 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16. März 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. März 2026, 20:50 UTC

Market Talk
Wichtige Nachrichtenereignisse

Energy & Utilities Roundup: Market Talk

16. März 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. März 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

16. März 2026, 19:53 UTC

Wichtige Nachrichtenereignisse

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16. März 2026, 19:43 UTC

Market Talk

Global Equities Roundup: Market Talk

16. März 2026, 19:43 UTC

Market Talk

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16. März 2026, 19:37 UTC

Market Talk
Wichtige Nachrichtenereignisse

Natural Gas Follows Oil Prices Lower -- Market Talk

16. März 2026, 19:20 UTC

Wichtige Nachrichtenereignisse

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16. März 2026, 19:17 UTC

Market Talk
Wichtige Nachrichtenereignisse

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16. März 2026, 19:00 UTC

Market Talk

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16. März 2026, 18:23 UTC

Market Talk

LME Restarts Trading After Outage -- Market Talk

16. März 2026, 17:36 UTC

Wichtige Nachrichtenereignisse

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16. März 2026, 17:19 UTC

Market Talk

Grains Sink as Investors Steer Toward Equities -- Market Talk

16. März 2026, 17:14 UTC

Wichtige Nachrichtenereignisse

Trump Ends News Conference

Peer-Vergleich

Kursveränderung

Charles River Laboratories International Inc Prognose

Kursziel

By TipRanks

32.44% Vorteil

12-Monats-Prognose

Durchschnitt 205.89 USD  32.44%

Hoch 265 USD

Tief 175 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Charles River Laboratories International Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

8

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

117.16 / 144.77Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

9 / 351 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat